Hepatocellular carcinoma: Molecular pathways and new therapeutic targets

被引:240
作者
Roberts, LR [1 ]
Gores, GJ [1 ]
机构
[1] Mayo Clin Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55902 USA
关键词
hepatocellular carcinoma; liver carcinogenesis; targeted therapy;
D O I
10.1055/s-2005-871200
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma is often diagnosed at an advanced stage, when it is not amenable to curative therapies. There is no effective chemotherapy. Advances in cancer biology suggest that a limited number of pathways are responsible for initiating and maintaining dysregulated cell proliferation, which is the major cellular alteration responsible for the cancer phenotype. New treatments in development target several of these critical pathways, including agents targeting the receptor tyrosine kinase pathways, the Wnt/beta-catenin signaling pathway, the ubiquitin/proteasome degradation pathway, the epigenetic DNA methylation and histone deacetylation Pathways, the PI3 kinase/AKT/mTOR pathway, angiogenic pathways, and telomerase. Several of these approaches hold significant promise for improving the long-term outcome of patients with advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, these approaches must be coupled with new strategies for halting or reversing the progression of chronic liver disease.
引用
收藏
页码:212 / 225
页数:14
相关论文
共 89 条
[1]   Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent [J].
Adjei, AA .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4276S-4280S
[2]  
Adjei AA, 2003, CLIN CANCER RES, V9, P115
[3]   Self-renewal and solid tumor stem cells [J].
Al-Hajj, M ;
Clarke, MF .
ONCOGENE, 2004, 23 (43) :7274-7282
[4]   Axis of evil: molecular mechanisms of cancer metastasis [J].
Bogenrieder, T ;
Herlyn, M .
ONCOGENE, 2003, 22 (42) :6524-6536
[5]   Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines [J].
Boon, EMJ ;
Keller, JJ ;
Wormhoudt, TAM ;
Giardiello, FM ;
Offerhaus, GJA ;
van der Neut, R ;
Pals, ST .
BRITISH JOURNAL OF CANCER, 2004, 90 (01) :224-229
[6]   Focus on hepatocellular carcinoma [J].
Bruix, J ;
Boix, L ;
Sala, M ;
Llovet, JM .
CANCER CELL, 2004, 5 (03) :215-219
[7]   The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications [J].
Burger, AM ;
Seth, AK .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2217-2229
[8]   Telomeres, telomerase, and myc.: An update [J].
Cerni, C .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2000, 462 (01) :31-47
[9]   Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].
Chan, S .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424
[10]  
Cheong JW, 2003, CLIN CANCER RES, V9, P5018